{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:07:02Z","timestamp":1778897222299,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2025.101080","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:28:29Z","timestamp":1766129309000},"page":"101080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy"],"prefix":"10.1016","volume":"46","author":[{"given":"Christina","family":"Quell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Blumenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veit L.","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ingenerf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel T.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2025.101080_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ctarc.2025.101080_bib0002","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ctarc.2025.101080_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ctarc.2025.101080_bib0004","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101080_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10254","key":"10.1016\/j.ctarc.2025.101080_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101080_bib0007","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101080_bib0008","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","article-title":"The International prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy","volume":"27","author":"Garcia-Recio","year":"2021","journal-title":"TransPlant Cell Ther."},{"issue":"14","key":"10.1016\/j.ctarc.2025.101080_bib0009","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.ctarc.2025.101080_bib0010","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ctarc.2025.101080_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.974029","article-title":"Lymphoma tumor burden before chimeric antigen receptor T-cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment","volume":"12","author":"Winkelmann","year":"2022","journal-title":"Front. Oncol."},{"issue":"27","key":"10.1016\/j.ctarc.2025.101080_bib0012","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.101080_bib0013","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jcyt.2023.03.007","article-title":"Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"25","author":"Winkelmann","year":"2023","journal-title":"Cytotherapy."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101080_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006659","article-title":"Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy","volume":"11","author":"Winkelmann","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2025.101080_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.664688","article-title":"Current and future role of medical imaging in guiding the management of patients with relapsed and refractory non-hodgkin lymphoma treated with CAR T-cell therapy","volume":"11","author":"Vercellino","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2025.101080_bib0016","series-title":"BASICS H\u00e4matologie","author":"Michl","year":"2023"},{"issue":"33","key":"10.1016\/j.ctarc.2025.101080_bib0017","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ctarc.2025.101080_bib0018","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101080_bib0019","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40644-022-00513-y","article-title":"Whole body FDG PET\/MR for progression free and overall survival prediction in patients with relapsed\/refractory large B-cell lymphomas undergoing CAR T-cell therapy","volume":"22","author":"Sj\u00f6holm","year":"2022","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101080_bib0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12149-020-01544-w","article-title":"(18)F-FDG PET\/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma","volume":"35","author":"Derlin","year":"2021","journal-title":"Ann. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101080_bib0021","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s003300050145","article-title":"Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus","volume":"7","author":"Prassopoulos","year":"1997","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101080_bib0022","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.ejrad.2009.08.013","article-title":"Splenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with age, gender, and anthropometric parameters","volume":"75","author":"Harris","year":"2010","journal-title":"Eur. J. Radiol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101080_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3892\/wasj.2020.80","article-title":"Splenic volume as a prognostic indicator for unresectable pancreatic cancer","volume":"3","author":"Suzuki","year":"2021","journal-title":"World Acad. Sci. J."},{"key":"10.1016\/j.ctarc.2025.101080_bib0024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/TCRM.S150968","article-title":"Increase in spleen volume as a predictor of oxaliplatin toxicity","volume":"14","author":"El Chediak","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101080_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030713","article-title":"Radiomics features of the spleen as surrogates for CT-based lymphoma diagnosis and subtype differentiation","volume":"14","author":"Enke","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101080_bib0026","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000907","article-title":"Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed\/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use","volume":"7","author":"B\u00fccklein","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101080_bib0027","first-page":"326","article-title":"Splenic involvement in lymphomas: evaluation on serial CT examinations","volume":"42","author":"Daskalogiannaki","year":"2001","journal-title":"Acta Radiol."},{"issue":"1009","key":"10.1016\/j.ctarc.2025.101080_bib0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1259\/bjr\/31542964","article-title":"Spleen in haematological malignancies: spectrum of imaging findings","volume":"85","author":"Saboo","year":"2012","journal-title":"Br. J. Radiol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101080_bib0029","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2214\/AJR.08.1160","article-title":"CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma","volume":"192","author":"de Jong","year":"2009","journal-title":"Am. J. Roentgenol."},{"issue":"8","key":"10.1016\/j.ctarc.2025.101080_bib0030","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdy219","article-title":"Surrogate end points in lymphoma","volume":"29","author":"Batlevi","year":"2018","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101080_bib0031","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41375-020-0963-1","article-title":"Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review","volume":"34","author":"Zhu","year":"2020","journal-title":"Leukemia"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225002163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225002163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:11:14Z","timestamp":1778893874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225002163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":31,"alternative-id":["S2468294225002163"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101080","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101080"}}